AstraZeneca Presents Positive Phase I/II Data for Surovatamig in B-cell ALL at EHA 2025

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results for AstraZeneca’s surovatamig, a next-gen CD19xCD3 bispecific T-cell engager (BiTE), were presented at the 2025 Congress of the European Hematology Association (EHA 2025). The event was held from June 12 to 15 in Milan, Italy.

The findings come from the global, multicenter, open-label, and single-arm Phase I/II SYRUS clinical trial (NCT06137118), which is evaluating surovatamig as a monotherapy for patients aged 12 and over with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). B-ALL is an aggressive hematologic malignancy that accounts for 7% to 85% of all acute lymphoblastic leukemia cases and is most commonly diagnosed in young children and adolescents, although its incidence also rises in older adults.

Surovatamig is designed with Fc-engineering for an extended half-life and optimized CD3 binding, which allows for intermittent dosing and controlled T-cell activation. This could offer a convenient and safer alternative to continuous infusion therapies like Blincyto. Beyond R/R B-ALL, surovatamig is also in Phase III trials as a monotherapy for diffuse large B-cell lymphoma and in combination with Biogen’s Rituxan (rituximab) for untreated follicular lymphoma. While surovatamig shows promise, it will need to demonstrate superior performance against established therapies such as Blincyto and Aucatzyl.

AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.